Navigation Links
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Date:4/28/2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID™ Phase 3 trials will be presented at the following medical meetings:Digestive Disease Week (DDW), McCormick Place, Chicago, ILMay 7-10, 2011Poster Presentation Information:Title:

Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. VancomycinPresenter:

Kathleen M. Mullane, D.O.Date:

Saturday, May 7, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Intestinal Disorders: Prebiotics, Probiotics and PathogensProgram #:

Sa1981Poster Presentation Information:Title:

High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 inPatients with C. difficile infection:  Combined Results of Two Phase 3 TrialsPresenter:

Pamela S. Sears, Ph.D. Date:

Monday, May 9, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Randomized Controlled Clinical TrialsProgram #:

Mo1160European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, ItalyMay 7-10, 2011 Oral Presentation Information:Title:

Immunosuppression and the Risk of Death, Cure Rates and Disease RecurrenceAmong Patients with Clostridium difficile InfectionPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011 Time:

10:36 a.m. to 10:48 a.m. Central European TimeLocation:

Lecture Hall Brown 1Oral Session:

C. difficile NewsPresentation #:

O504Poster Presentation Information:Title:

Cl
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... of the most promising technologies for future quantum circuits ... instead of electrons. First, it is necessary to be ... control their direction. Researchers around the world have made ... now scientists at the Niels Bohr Institute have succeeded ... at a time and in a particular direction. The ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 ... valued at $5.6 billion in 2019. It is ... from 2013 to 2019, and was valued at ... report published by Transparency Market Research. , For ... visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... breath, sweat and skin have been used to detect humans ... of portable sensors for use in real-life situations, such as ... disasters in New Zealand and Japan. Published today, Monday ... , the study examined flumes of air to create a ...
... , Bochum,s physicists led by Prof. Dr. Hartmut Zabel ... for the first time experimentally. The behaviour of the ... research team at the RUB has now succeeded in ... resolution. Through their rotation of the magnetic moments, the ...
... Ore. -- A collaborative Oregon State University-University of Oregon ... Science Foundation grant in 2008, is moving into a ... The new NSF funding, awarded through its Centers ... Sustainable Materials Chemistry to expand research and development and ...
Cached Biology Technology:Scientists utilize breath and sweat to detect trapped humans 2Spin pumping effect proven for the first time 2Center for Sustainable Materials Chemistry gets Phase 2 NSF grant 2Center for Sustainable Materials Chemistry gets Phase 2 NSF grant 3Center for Sustainable Materials Chemistry gets Phase 2 NSF grant 4
(Date:8/29/2014)... of the Tibetan plateau -- the largest topographic anomaly ... both its profound effect on climate and its reflection ... GSA Bulletin , Katharine Huntington and colleagues employ a ... modern and fossil snail shells to investigate the uplift ... , Views range widely on the timing of surface ...
(Date:8/28/2014)... America (ESA) is pleased to announce the selection of ... Society. Honorary Membership acknowledges those who have served ESA ... the affairs of the Society that has reached an ... the ESA Governing Board and then voted on by ... the Awards Ceremony at Entomology 2014, ESA,s Annual Meeting ...
(Date:8/28/2014)... reports that an expansion of marine protected areas is ... functions. According to investigators from the Wildlife Conservation ... have focused on saving the largest numbers of species, ... key and difficult-to-replace ecological functions. , Many ... fish species that also are food for millions of ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... Howard Hughes Medical Institute (HHMI) scientists has peeled back some ... off genes selectively to control critical events of development. The ... the structure of Dicer, an enzyme that enables cells to ... in the January 13, 2005, issue of the journal Science ...
... Biobank, a visionary medical project aimed at improving the ... and many other serious conditions is launched this week ... three thousand people living in the south Manchester area ... before it goes nationwide later this year. , They ...
... at the University of Minnesota Medical School have discovered a ... have properties of primitive stem cells. , Umbilical ... that can only produce cells found in blood. The ... cells with the characteristics of more primitive stem cells that ...
Cached Biology News:Molecule does more than slice and dice RNA 2Molecule does more than slice and dice RNA 3Molecule does more than slice and dice RNA 4Multi-million pound UK Biobank underway 2Multi-million pound UK Biobank underway 3
Request Info...
... the 4300 System features Saga GT , ... SagaGT automates electrophoresis, lane finding, location of ... scoring. ,Saga GT is second generation ... was initially developed at the University of ...
... Polynucleotide Kinase (PNK) catalyzes the transfer ... the 5'-hydroxyl of single- and double-stranded ... enzyme also removes the 3'-phosphate from ... 3', 5'-diphosphates to form a 3'-hydroxyl ...
Request Info...
Biology Products: